Tenascin-C as predictor of left ventricular remodeling and mortality in patients with dilated cardiomyopathy

Journal of Investigative Medicine

Volumn 61, Issue 4, 2013, Pages 728-732

  Sarli, Bahadir ^a   Topsakal, Ramazan ^a   Kaya, Esma G ^b   Akpek, Mahmut ^a   Lam, Yat Yin ^c   Kaya, Mehmet G ^a  

^a Kayseri Education and Research Hospital ^*  (Turkey)

^b ERCIYES UNIVERSITY   (Turkey)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Dilated cardiomyopathy; Reverse remodeling; Tenascin C

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; CARVEDILOL; FUROSEMIDE; RAMIPRIL; SPIRONOLACTONE; TENASCIN;

AGED; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORRELATIONAL STUDY; DIABETES MELLITUS; DRUG TOLERANCE; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTOR VARIABLE;

AGED; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; CARBAZOLES; CARDIOMYOPATHY, DILATED; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; FEMALE; FUROSEMIDE; HEART FUNCTION TESTS; HONG KONG; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPANOLAMINES; RAMIPRIL; SPIRONOLACTONE; SURVIVAL RATE; TENASCIN; TETRAZOLES; TURKEY; VENTRICULAR REMODELING;

EID: 84877889083     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e3182880c11     Document Type: Article

References (23)

1. Terasaki F, Okamoto H, Onishi K, et al, and Study Group for Intractable Diseases by a Grant from the Ministry of Health, Labor and Welfare of Japan. Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. Circ J. 2007;71:327-330.
2. American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 2000.
3. Vatankulu MA, Goktekin O, Kaya MG, et al. Effect of long-term resynchronization therapy on left ventricular remodeling in pacemaker patients upgraded to biventricular devices. Am J Cardiol. 2009;9:1280-1284.
4. Nilsson JC, Groenning BA, Nielsen G, et al. Left ventricular remodeling in the first year after acute myocardial infarction and the predictive value of N-terminal pro brain natriuretic peptide. Am Heart J. 2002;143:696-70.
5. Kaya MG, Ozdogru I, Kalay N, et al. Plasma B-type natriuretic peptide in diagnosing inferior myocardial infarction with right ventricular involvement. Coron Artery Dis. 2008;8:609-613.
6. Kaya MG, Lam YY, Erer B, et al. Long term effect of bosentan therapy on cardiac function and symptomatic benefits in adult patients with Eisenmenger syndrome. J Card Fail. 2012;18(5):379-384.
7. Kaya MG, Yalcin R, Okyay K, et al. Potential role of plasma myeloperoxidase level in predicting long-term outcome of acute myocardial infarction. Tex Heart Inst J. 2012;39(4):500-506.
8. Golledge J, Clancy P, Maguire J, et al. The role of tenascin C in cardiovascular disease. Cardiovasc Res. 2011;92:19-28.
9. Ballard VL, Sharma A, Duignan I, et al. Vascular tenascin-C regulates cardiac endothelial phenotype and neovascularization. FASEB J. 2006;20:717-719.
10. Frangogiannis NG, Shimoni S, Chang S, et al. Active interstitial remodeling: an important process in the hibernating human myocardium. J Am Coll Cardiol. 2002;39:1468-1474.
11. Sato A, Aonuma K, Imanaka-Yoshida K, et al. Serum tenascin-c might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. J Am Coll Cardiol. 2006;47:2319-2325.
12. Sato A, Hiroe M, Akiyama D, et al. Prognostic value of serum tenascin-C levels on long-term outcome after acute myocardial infarction. J Card Fail. 2012;18(6):480-486.
13. American Society of Echocardiography Committee on Standards, Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantification of the left ventricle by two-dimensional echocardiography. J Am Soc Echo. 1989;2:358-367.
14. Aso N, Tamura A, Nasu M. Circulating Tenascin-C levels in patients with idiopathic dilated cardiomyopathy. Am J Cardiol. 2004;94(11):1468-1470.
15. Tamura A, Kusachi S, Nogami K, et al. Tenascin expression in endomyocardial biopsy specimens in patients with dilated cardiomyopathy: distribution along margin of fibrotic lesions. Heart. 1996;75:291-294.
16. Nishioka T, Onishi K, Shimojo N, et al. Tenascin-C may aggravate left ventricular remodeling and function after myocardial infarction in mice. Am J Physiol Heart Circ Physiol. 2010;98:H1072-H1078.
17. Imanaka-Yoshida K, Hiroe M, Nishikawa T, et al. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab Invest. 2001;81:1015-1024.
18. Morimoto S, Imanaka-Yoshida K, Hiramitsu S, et al. Diagnostic utility of tenascin-C for evaluation of the activity of human acute myocarditis. J Pathol. 2005;205:460-467.
19. Hessel M, Bleeker GB, Bax JJ, et al. Reverse ventricular remodeling after cardiac resynchronization therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels. Eur J Heart Fail. 2007;9(10):1058-1063.
20. Willems IE, Arends JW, Daemen MJ. Tenascin and fibronectin expression in healing human myocardial scars. J Pathol. 1996;179:321-325.
21. Tamaoki M, Imanaka-Yoshida K, Yokoyama K, et al. Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am J pathol. 2005;167:71-80.
22. Imanaka-Yoshida K, Hiroe M, Yasutomi Y, et al. Tenascin-C is a useful marker for disease activity in myocarditis. J Pathol. 2002;197:388-394.
23. Imanaka-Yoshida K, Hiroe M, Yoshida T. Interaction between cell and extracellular matrix in heart disease: multiple roles of tenascin-C in tissue remodeling. Histol Histopathol. 2004;19:517-525.